Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis

U Modlich, OS Kustikova, M Schmidt, C Rudolph… - Blood, 2005 - ashpublications.org
U Modlich, OS Kustikova, M Schmidt, C Rudolph, J Meyer, Z Li, K Kamino, N Von Neuhoff…
Blood, 2005ashpublications.org
Previous studies have demonstrated leukemic complications in mice after high-copy
retroviral gene transfer of the multidrug resistance 1 (MDR1) cDNA, encoding a membrane-
located efflux pump expressed in hematopoietic stem cells. In contrast, no such
complications or MDR1-associated alterations of hematopoiesis were observed in
numerous other studies exploring MDR1 gene transfer into cell lines, mice, dogs, nonhuman
primates, and human subjects. Here, we show that leukemias associated with retroviral …
Abstract
Previous studies have demonstrated leukemic complications in mice after high-copy retroviral gene transfer of the multidrug resistance 1 (MDR1) cDNA, encoding a membrane-located efflux pump expressed in hematopoietic stem cells. In contrast, no such complications or MDR1-associated alterations of hematopoiesis were observed in numerous other studies exploring MDR1 gene transfer into cell lines, mice, dogs, nonhuman primates, and human subjects. Here, we show that leukemias associated with retroviral expression of MDR1 depend on high vector dose, and involve the selection of clones with combinatorial insertional mutagenesis of proto-oncogenes or other signaling genes. Compared with insertion patterns in normal long-term repopulating hematopoietic cells, such hits were overrepresented in leukemic clones, pointing to a causal role. A similar constellation of insertion sites was also observed in a leukemia arising after high-copy retroviral gene transfer of a fluorescent protein. Spectral karyotyping demonstrated additional chromosomal translocations in a subset of cases, indicative of secondary genetic instability. We also show that insertional mutants can be amplified in vitro prior to transplantation. On the basis of these findings, we suggest the use of preclinical dose-escalation studies to define a therapeutic index for retroviral transgene delivery.
ashpublications.org